1. Taiwan Stocks

  2. •

    Retail trade

  3. •

    Department stores
MARX Biotech Co., Ltd.

MARX Biotech Co., Ltd.

TTPEX:7731
4.09
TWD
0.00
(0.00%)
2.83BMarket Cap
MARX Biotech Co., Ltd.
TPEX:7731
(Taipei Exchange)

Recent

price

4.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
TWD
- -
0.35
0.32
0.9
1.24
1.22
- -
Revenue per Share
- -
0.05
0.01
-0.04
-0.19
0.08
- -
Basic EPS, GAAP
- -
-0.06
0.03
-0.06
-0.65
-0.31
- -
Free Cash Flow per Basic Share
- -
- -
0.02
0.02
- -
- -
- -
Dividend per Share
- -
0.13
0.12
0.59
0.5
0.69
0.55
Book Value per Share
- -
0.13
0.12
0.52
0.31
0.56
0.43
Tangible Book Value per Share
321
276
347
321
498
522
518
Basic Weighted Avg Shares
- -
98
111
290
618
636
- -
Sales/Revenue/Turnover
- -
17.3
1.71
-4.94
-12.52
-21.93
- -
Operating Margin (%)
- -
1
2
5
18
20
- -
Depreciation Expense
- -
14
3
-13
-97
43
- -
Net Income, GAAP
- -
21.92
42.3
- -
- -
26.99
- -
Effective Tax Rate (%)
- -
14.12
2.56
-4.46
-15.66
6.75
- -
Profit Margin (%)
- -
64
55
242
99
240
156
Working Capital
- -
1
1
1
170
164
149
LT Debt
- -
66
61
293
251
359
289
Total Equity
- -
32.92
0.69
- -
- -
-17.23
- -
Return on Invested Capital (%)
- -
40.8
4.07
- -
- -
8.97
- -
Return on Capital (%)
- -
42
4.48
-7.3
-35.58
14.06
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
198
144
71
LT Borrowings
172
164
149
LT Finance Leases
4
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
507
522
522
Market Capitalization
2,580
2,516
2,829

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
396
548
391
Cash, Cash Equivalents & STI
28
35
73
Accounts Receivable, Net
86
67
83
Inventories
244
110
89
Total Current Liabilities
342
308
235
Payables & Accruals
- -
- -
- -
ST Debt
198
144
71
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
43.04%
Free Cash Flow
- -
- -
-50.01%
Net Income, GAAP
- -
- -
-144.33%
Sales/Revenue/Turnover
- -
- -
2.85%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
618
2025
- -
- -
636
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.19
2025
- -
- -
0.08
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
PDD Holdings Inc. (NASDAQ:PDD)
Macy's Inc (NYSE:M)
Magazine Luiza S.A. (B3:MGLU3)
Kohl's Corporation (NYSE:KSS)
Dollarama Inc. (TSX:DOL)
Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI)
Business
MARX Biotech Co., Ltd. (7731.TWO) operates as a Taiwan-based retailer specializing in health and wellness products, focusing on data-driven innovation in the big health retail market through online and multi-channel distribution. Founded in 2021 and headquartered in New Taipei City, Taiwan, the company offers a diverse portfolio of core brands and products including TAIZAKU for men's health supplements; Phargoods for fitness and children's nutritional supplements; SnowIOU for women's health and beauty care; inyouso for skincare and probiotics; Diu+ for influencer-driven wellness items; and dr.hold for women's hygiene products such as vaginal tightening gels, yoni washes, intimate oils, and hair removal creams; alongside broader categories spanning health foods, cosmeceuticals, hair care, and cleaning products sold via e-commerce platforms, brand websites, pharmacies, medical facilities, live streaming, telemarketing, and overseas cross-border channels. MARX Biotech listed on the Taipei Exchange Emerging Stock Market in February 2024 and has pursued aggressive growth through strategic acquisitions since 2023, including Phargoods, SnowIOU, dr.hold, and ANB to bolster telemarketing capabilities; a recent collaboration with Top International Biotech to acquire product patents, trademarks, and inventory for entry into pharmaceutical and medical device wholesale; marking its expansion into broader healthcare ecosystems and medical institution channels while enhancing operational efficiency and high-margin (over 70%) portfolio integration. The company targets consumer niches in men's, women's, fitness, maternal-child, and skincare health segments primarily in Taiwan with international e-commerce reach, leveraging consumer data from over 600,000 members and B2B pharmacy systems to drive product development and above-industry revenue growth of 162% in 2023 and 109% in 2024.